Hepatitis B Treatment: What We Know Now and What Remains to Be Researched by Suk‐fong Lok, Anna
8REVIEWS | Hepatology CommuniCations, Vol. 3, no. 1, 2019  
Hepatitis B Treatment: What We Know 
Now and What Remains to Be Researched
Anna Suk-Fong Lok
Chronic hepatitis B virus (HBV) infection remains a major global health burden. Currently, two types of treatment, 
interferons (IFNs) and nucleos(t)ide analogues (NAs), have been approved. These treatments are effective in sup-
pressing HBV replication and in decreasing the risk of developing cirrhosis, liver failure, hepatocellular carcinoma 
(HCC), and death. However, these treatments do not eliminate the virus, and the risk of HCC remains. This 
review article summarizes current knowledge about the safety, efficacy, and clinical indications of hepatitis B treat-
ment. It also discusses limitations of existing treatment, gaps in knowledge, and feasibility of a hepatitis B cure. 
(Hepatology Communications 2019;3:8-19).
Chronic hepatitis B virus (HBV) infection remains a major global health burden affecting 292 mil-lion persons worldwide.(1) Treatments that are 
effective in suppressing HBV replication are interferons 
(IFNs) and nucleos(t)ide analogues (NAs); these have 
been available for nearly 2 decades but do not eliminate 
the virus. IFNs and NAs have been demonstrated to 
prevent cirrhosis, liver failure, and hepatocellular carci-
noma (HCC),(2) but the risk of HCC remains, even for 
patients in whom the virus is suppressed. Thus, there 
is a need to develop “curative” therapies for hepatitis 
B. Equally important is the need to improve diagnosis 
and linkage to care. Globally, it is estimated that only 
10% of persons chronically infected with HBV have 
been diagnosed and only 5% of those who are eligible 
for treatment have received treatment.(1)
HBV Biology and Barriers 
to Cure
HBV RepliCation CyCle
HBV is a hepatotropic DNA virus that replicates 
by means of reverse transcription of a pregenomic 
RNA. The life cycle of HBV is depicted in Fig. 1.(3) 
The circulating virion comprises an envelope and a 
nucleocapsid that contains a partially double-stranded, 
relaxed, circular DNA. The entry receptor of HBV has 
been identified to be sodium taurocholate cotransport-
ing polypeptide, which explains the hepatotropism 
of HBV. Following entry into the hepatocyte, the 
envelope is shed and the nucleocapsid is transported 
into the nucleus where the partially double-stranded, 
relaxed, circular DNA is repaired and the covalently 
closed circular DNA (cccDNA) is bound to chro-
matin. The cccDNA is transcribed into pregenomic 
RNA, which is then reverse transcribed into HBV 
DNA. The pregenomic RNA is also transcribed into 
viral messenger RNAs and in turn translated into the 
following viral proteins: surface (large, middle, and 
small surface proteins), core (hepatitis B core anti-
gen as well as precore/core from which hepatitis B e 
antigen [HBeAg] is derived), polymerase (which also 
functions as a reverse transcriptase), and X (unclear 
functions but may play a role in cccDNA transcrip-
tion). The nucleocapsid is assembled in the cytoplasm 
and contains the pregenomic RNA as well as core and 
polymerase proteins. The pregenomic RNA is reverse 
transcribed into the (–) strand HBV DNA, which 
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serves as a template for the (+) strand HBV DNA; 
however, the virion is enveloped and secreted before 
the (+) strand HBV DNA is completely synthesized. 
Nucleocapsids can be recycled from the cytoplasm 
back into the nucleus, and thus cccDNA can be 
replenished without the need for entry of new virions. 
cccDNA has a long half-life, and its elimination in 
untreated patients appears to be predominantly medi-
ated through loss of infected hepatocytes.
meCHanisms oF aCtion oF na 
anD iFn
NAs inhibit reverse transcription of pregenomic 
RNA and synthesis of HBV DNA in the cyto-
plasm and have no direct effect on cccDNA. IFN 
has both antiviral and immunomodulatory activities, 
although the precise mechanisms of action remain 
unclear. Recent studies suggest that IFN may enhance 
cccDNA degradation and exert epigenetic modifica-
tion of cccDNA transcription,(4) explaining its greater 
effect on viral protein production and higher rates of 
HBeAg and hepatitis B surface antigen (HBsAg) loss 
compared to NAs.
BaRRieRs to eliminating HBV
Persistence of cccDNA and its ability to self-replen-
ish and the lack of direct effects of current therapies 
on cccDNA account for the difficulty in eliminating 
cccDNA. There are additional barriers to eliminating 
HBV. HBV DNA can be integrated into the host 
genome. Although integrated HBV DNA is often 
rearranged and/or partially deleted and there is no 
evidence that it supports the full cycle of HBV rep-
lication, recent studies suggest that integrated HBV 
DNA can be sufficiently intact to support translation 
of viral proteins, e.g., HBsAg.(5) Elimination of inte-
grated HBV DNA will likely require the removal of 
hepatocytes that harbor these DNA. Control of infec-
tions generally requires elimination of the infectious 
organisms coupled with activation of specific immune 
responses. Whereas patients who recover from acute 
HBV infection display rigorous immune responses to 
multiple HBV epitopes, patients with chronic HBV 
infection manifest weak immune responses to very 
few HBV epitopes.(6)
Persistence of cccDNA, presence of integrated 
HBV DNA, and impaired innate and adaptive 
immune responses explain why it would be difficult 
to eliminate HBV from patients who are chronically 
infected. Indeed, HBV persists in the livers of persons 
who have recovered from acute HBV infection with 
HBsAg to hepatitis B surface antibody seroconversion. 
Thus, HBV reactivation can occur when “recovered” 
individuals receive potent immunosuppressive therapy, 
such as anti-clusters of differentiation (CD)20, and 
transmission of HBV infection can occur when livers 
from these individuals are transplanted into seroneg-
ative recipients.
Phases of Chronic HBV 
Infection
The course of chronic HBV infection is charac-
terized by fluctuations in HBV DNA and alanine 
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aminotransferase (ALT) levels, reflecting variations 
in the balance between HBV replication and host 
immune response. Traditionally, three clinical parame-
ters (HBeAg status, HBV DNA level, and ALT level) 
are used to define the four phases of chronic HBV 
infection (Fig. 2).
During the first phase, patients are HBeAg-
positive with high HBV DNA (>7 log10 IU/mL) but 
normal ALT levels. These patients are considered to 
be in the “immune tolerant” phase, although recent 
studies showed that HBV-specific T-cell responses 
during this phase are not significantly different from 
those in active phases and that this phase should be 
renamed “low inflammatory” phase.(7) During the 
second “HBeAg-positive chronic hepatitis” phase, 
ALT becomes elevated. After varying durations, 
Fig. 1. HBV lifecycle and antiviral targets.(3) HBV entry: Lipopeptides mimicking pre-S1 domain competing with a Dane particle 
for binding to NTCP (e.g., Myrcludex B); other small molecule inhibitors are in development. Targeting cccDNA: Prevention of 
cccDNA formation; damage and destruction through cytokines or cccDNA sequence-specific nucleases; functional silencing through 
modulation of host cellular epigenetic-modifying enzymes by cytokines or inhibition of viral protein function. HBV mRNAs: Small 
interfering RNA approaches or anti-sense oligonucleotides to block viral replication and viral protein expression. HBV polymerase: 
Reverse transcriptase inhibitors include approved NAs; RNAse H inhibitors are in preclinical evaluation. Nucleocapsid assembly and 
pgRNA packaging: Capsid assembly modulators can affect nucleocapsid assembly and pgRNA encapsidation and may affect the nuclear 
functions of HBc (cccDNA regulation and IFN-stimulated gene expression). Targeting HBsAg: Phosphorothioate oligonucleotides 
nucleic acid polymer inhibiting HBsAg release and monoclonal antibodies to decrease circulating HBsAg load are under evaluation. 
Abbreviations: dslDNA, double-stranded linear DNA; HBc, hepatitis B core protein; HBe, hepatitis B e protein; HBs, hepatitis 
B surface antigen; HBx, hepatitis B x protein; mRNA, messenger RNA; MVB, multivesicular body; NTCP, sodium taurocholate 
cotransporting polypeptide; pgRNA, pregenomic RNA; Pol, polymerase; rcDNA, relaxed circular DNA; RNAse H, ribonuclease H.
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seroconversion from HBeAg to hepatitis B e antibody 
occurs. In some instances, this may be accompanied by 
ALT flares and even hepatic decompensation. After 
HBeAg loss, most patients enter the third “inactive 
carrier” phase. Patients in this phase are HBeAg-
negative and have low (<2,000 IU/mL) or unde-
tectable HBV DNA and normal ALT. Prognosis is 
generally favorable if there had not been significant 
liver injury before entry to this phase and patients 
remain in this phase. Some patients directly transition 
from the HBeAg-positive chronic hepatitis phase to 
the fourth “HBeAg-negative chronic hepatitis” phase, 
whereas most enter this phase after varying durations 
in the inactive carrier phase. Patients in the HBeAg-
negative chronic hepatitis phase are HBeAg-negative 
and have moderate to high HBV DNA (3-7 log10 IU/
mL) levels and elevated ALT. Although most patients 
progress from one phase to the next sequentially, rever-
sion to the previous phase can occur. Furthermore, 
depending on the HBV DNA and ALT cut-off 
values used to define these phases, as many as 30% 
to 40% of patients do not fit into any phase. Many of 
these patients may be in transition from one phase to 
another, whereas some with low viremia and elevated 
ALT may have concomitant causes of liver injury, 
most commonly nonalcoholic fatty liver disease.
Recent studies have shown that quantification of 
serum HBsAg levels can help in differentiating the 
phases of HBV infection; levels are highest in the 
immune tolerant phase and lowest in the inactive car-
rier phase. Quantitative HBsAg levels are most useful 
in differentiating whether a patient who is HBeAg-
negative with low HBV DNA is truly in the inac-
tive carrier phase or in the quiescent period of the 
HBeAg-negative chronic hepatitis phase and in pre-
dicting risk of HCC.(8,9)
Eventually, some patients spontaneously clear 
HBsAg. HBsAg loss is reported to occur at the rate of 
0.5% to 1% per year, but the incidence is not linear.(10) 
Risk of adverse clinical outcomes is greatly reduced 
Fig. 2. Phases of chronic HBV infection.(3) Traditionally, phases of chronic HBV infection are defined by HBeAg status, serum HBV 
DNA, and ALT levels. Quantitative HBsAg levels are different in each phase and are generally highest in the immune tolerant phase 
and lowest in the inactive carrier phase. Although most patients progress from one phase to the next, not all patients go through each 
phase; reversion to an earlier phase can occur. Immune tolerant: HBeAg-positive, high serum HBV DNA but normal ALT levels. 
Immune clearance/HBeAg-positive chronic hepatitis: HBeAg-positive, high serum HBV DNA, and elevated ALT levels; HBeAg 
seroconversion to anti-HBe occurs after varying durations. Inactive carrier: HBeAg-negative, serum HBV DNA low (generally <2,000 
IU/mL) or undetectable. Reactivation/HBeAg-negative chronic hepatitis: HBeAg-negative, elevated levels of HBV DNA and ALT in 
serum, HBV precore and/or basal core promoter variant often present. Abbreviation: HBsAg, hepatitis B surface antigen.
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after HBsAg loss, but risk of HCC remains if HBsAg 
loss occurs after age 50 years or cirrhosis development 
or in the presence of hepatitis C or D coinfection.(11) 
Currently, HCC surveillance is recommended for 
those who lost HBsAg after age 50 or after cirrho-
sis development, but it is unclear if this needs to be 
continued for life because the risk may decrease over 




The goals of hepatitis B treatment are to prevent 
the development of cirrhosis, liver failure, HCC, and 
HBV-related deaths. Proving that treatment improves 
clinical outcomes will require years if not decades of 
surveillance. Thus, surrogate markers consisting of 
biochemical (normalization of ALT), virologic (sup-
pression of serum HBV DNA to undetectable using 
sensitive real-time polymerase chain reaction assays 
with detection limits of 10-20 IU/mL), serologic 
(HBeAg and/or HBsAg loss with or without sero-
conversion to hepatitis B e antibody and hepatitis B 
surface antibody), and histologic (decrease in hepatic 
inflammation with or without reversal of fibrosis) 
tests have been used to measure efficacy of treatment.
inDiCations FoR tReatment
Chronic HBV infection, if acquired at a young 
age and if left untreated, is associated with a 20% to 
40% lifetime risk of HBV-related mortality. However, 
as described above, spontaneous virologic and clini-
cal remissions with HBeAg and even HBsAg loss 
can occur. Thus, not all patients require treatment. 
Indications for treatment depend on the activity and 
severity of liver disease at presentation; for those with 
no cirrhosis at presentation, indications for treatment 
depend on the predicted risk of cirrhosis or HCC in 
the future. Various models have been developed to 
predict the risk of HCC. Variables included in each 
model differ but generally include demographics (sex, 
age), HBV markers (HBeAg status, HBV DNA level, 
and some also include HBV genotype and quantitative 
HBsAg), and liver disease parameters (ALT, platelets 
as a marker of cirrhosis/portal hypertension, cirrhosis 
status, or liver stiffness measurement as a marker of 
liver fibrosis). Although some of these models have 
been validated in external cohorts, prospective valida-
tion of these models in determining indications for 
treatment, intensity of monitoring, and need for HCC 
surveillance has not been performed.
The American Association for the Study of Liver 
Diseases (AASLD), the Asian Pacific Association for 
the Study of the Liver (APASL), and the European 
Association for the Study of the Liver (EASL) guide-
lines recommend antiviral treatment for patients with 
decompensated cirrhosis regardless of HBV DNA or 
ALT levels.(12-15) Treatment is also recommended for 
patients with compensated cirrhosis and detectable 
serum HBV DNA regardless of ALT level. Patients 
with severe exacerbations of chronic hepatitis B (ALT 
flares with accompanying increase in bilirubin) and 
those with acute liver failure are also recommended 
to receive antiviral treatment. Although high-quality 
evidence to support these indications is not available, 
the potential benefits are undisputed and the possible 
risks are small. Of note, the landmark double-blind 
randomized trial demonstrating a benefit of lamivu-
dine versus placebo in reducing disease progression 
(defined as increase in Child-Turcotte-Pugh score by 
≥2 points, clinical decompensation, HCC, or death) 
in patients with bridging fibrosis or cirrhosis enrolled 
patients with baseline serum HBV DNA >~140,000 
IU/mL.(16) Since then, several studies have suggested 
a benefit of treatment in patients with compensated 
cirrhosis and lower HBV DNA levels (including 
those with HBV DNA <2,000 IU/mL).
For patients with no cirrhosis at presentation, 
guidelines recommend treatment for those with 
chronic hepatitis, both HBeAg-positive or HBeAg-
negative. Although HBV DNA levels are highest 
in the immune tolerant phase, current guidelines do 
not recommend treatment for patients in this phase 
because the likelihood of treatment-induced HBeAg 
loss is extremely low. In one study comparing teno-
fovir disoproxil fumarate (TDF) monotherapy versus 
TDF plus emtricitabine, HBV DNA was suppressed 
to <69 IU/mL in 65% of patients, HBeAg loss 
occurred in 3% of patients, and HBsAg loss occurred 
in none of the patients at the end of 4 years of treat-
ment; relapse occurred in all patients when treatment 
was discontinued.(17)
Recognizing that persistently high HBV DNA lev-
els and having a family history of HCC increase the 
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risk of HCC,(18,19) guidelines recommend treatment 
if patients remain in the immune tolerant phase after 
the age of 30 to 40 years or if there is a family his-
tory of HCC. The AASLD guidelines used age 40 
as the cutoff based on data from a study showing the 
risk of cirrhosis development increased from 1.1% 
to 4.1% to 28% in patients who lost HBeAg before 
age 30, between 30 and 39, and after age 40, respec-
tively.(20) By contrast, the EASL guidelines selected 
age 30 as the cutoff. It is unclear which cutoff is more 
appropriate. Many experts have advocated for treat-
ment early in the course of infection to minimize liver 
injury, integration of HBV DNA, and risk of HCC. 
However, it is unclear whether initiating treatment in 
the immune tolerant phase will prevent integration of 
HBV DNA because integration can occur early and 
can be detected in children. Similarly, although there 
is clear evidence that patients with a family history 
of HCC are at increased risk of HCC, it is unclear 
whether the risk is related to the number of fam-
ily members affected, the biological relationships to 
the affected family members, and the age of family 
members when HCC was diagnosed. It is also unclear 
whether antiviral therapy initiated in the absence of 
standard indications will prevent HCC in patients 
who are genetically predisposed, are infected with an 
unusually virulent strain of HBV, or had been exposed 
to environmental carcinogens. Answers to these ques-
tions may be irrelevant if one day simple, safe, highly 
effective curative treatments similar to direct-act-
ing antivirals for hepatitis C become available when 
universal treatment would be recommended. In the 
meantime, studies that can provide answers to these 
nuances would be informative.
Another group of patients in the immune tolerant 
phase for which antiviral treatment is recommended 
are women with high viremia (>200,000 IU/mL).(13) 
Several studies showed that administration of antiviral 
therapy to these mothers in the third trimester of preg-
nancy further reduced the risk of mother-to-child trans-
mission in newborns who received hepatitis B immune 
globulin (HBIG) and the HBV vaccine at birth.(21,22) 
This benefit was not observed in a recent study 
where administration of HBIG and birth dose HBV 
vaccine occurred immediately after birth (median, 
1.2-1.3 hours) and a total of five versus three doses 
of HBV vaccine were administered.(23) Further stud-
ies to determine whether more timely administration 
of HBIG and birth dose HBV vaccine to newborns 
might obviate the need for antiviral therapy in highly 
viremic mothers is warranted. Some experts have 
indicated that TDF is more readily available and at a 
lower cost than HBIG in resource-limited countries; 
however, HBV DNA testing is also not readily avail-
able in these countries, making it difficult to differen-
tiate high versus low viremic carrier mothers.
Antiviral therapy is also recommended as prophy-
laxis for patients who are HBsAg-positive as well as 
patients who are HBsAg-negative and hepatitis B core 
antibody-positive who require treatment with immu-
nosuppressive therapies that are predicted to have 
a moderate to high risk of HBV reactivation.(13) A 
major challenge is in assessing the risk of HBV reac-
tivation associated with immunosuppressive or cancer 
therapies because new drugs and biologics come on 
the market every month, a combination of drugs are 
frequently used, and treatment may be modified if 
initial response is unsatisfactory.
eFFiCaCy anD saFety oF 
aVailaBle tReatments
Currently, two types of treatment, IFNs and NAs, 
are approved for chronic HBV infection. The viro-
logic responses to these therapies are summarized in 
Table 1.(13,24,25) Pegylated IFNs have a more conve-
nient dosing schedule (once versus thrice weekly) 
and improved efficacy. Among the NAs, entecavir 
(ETV), TDF, and tenofovir alafenamide (TAF) are 
preferred because of their potent antiviral activity and 
high barrier to antiviral resistance. A 1-year course of 
pegylated IFN results in higher rates of HBeAg sero-
conversion (~30% versus 10%-21%) and HBsAg loss 
(3% versus <1%-3%) than the same duration of ETV, 
TDF, or TAF therapy in patients who are HBeAg-
positive despite lower rates of undetectable HBV 
DNA (25% versus 61%-76%). Similarly, in patients 
who are HBeAg-negative, a 1-year course of pegylated 
IFN results in a higher rate of HBsAg loss (4% ver-
sus 0%-1%) than the same duration of ETV, TDF, 
or TAF therapy despite a lower rate of undetectable 
HBV DNA (63% versus 90%-94%). Response to IFN 
is more durable, and rates of HBeAg and HBsAg 
loss continue to increase after cessation of treatment, 
whereas viral relapse is universal when NA is discon-
tinued after 1 year of therapy.
Follow-up of patients for 3 to 4 years after com-
pletion of a 1-year course of pegylated IFN showed 
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that HBsAg loss increased to 8%. By contrast, con-
tinuous treatment with NA for up to 5 years has not 
been shown to further increase the rate of HBsAg 
loss except for one study of TDF in patients who 
were HBeAg-positive where the rate of HBsAg loss 
increased to 10%. The low rate of HBsAg loss is 
related to the lack of direct effect of IFN and NA 
on cccDNA; thus, despite suppression of HBV DNA 
replication, cccDNA persists and transcription of 
pregenomic RNA and translation of viral protein con-
tinues. Furthermore, it is now recognized that inte-
grated HBV DNA can also be a source of circulating 
HBsAg.
IFN has to be administered as injections and is 
associated with numerous adverse effects. It is con-
traindicated in patients with decompensated cirrhosis 
or severe exacerbations of chronic hepatitis and those 
with autoimmune or psychiatric illnesses and must 
be used with caution in patients with compensated 
cirrhosis. By contrast, NAs are administered orally 
and have negligible adverse effects, and risk of anti-
viral drug resistance is ≤1% after >5 years of contin-
ued treatment with ETV or TDF. NAs can be safely 
administered in patients with decompensated cirrho-
sis, HCC, severe exacerbations of chronic hepatitis, or 
acute liver failure. ETV was reported to be associated 
with lactic acidosis in one case series of hospitalized 
patients with decompensated cirrhosis, but other 
causes, such as sepsis, may have contributed to lactic 
acidosis in these acutely sick patients. Mitochondrial 
toxicity and lactic acidosis are potential adverse effects 
of all NAs, but documented associations with ETV, 
TDF, or TAF are extremely rare. TDF has been doc-
umented to decrease glomerular filtration rate as well 
as renal tubular function and to decrease bone mineral 
density. Although population studies suggest that the 
incidence of adverse events is low,(26) given the need 
for long durations of NA therapy and increasing age 
of patients with chronic hepatitis B, safer alternatives 
are preferred. TAF is a new prodrug of tenofovir. TAF 
in doses of 25 mg has similar antiviral activity as TDF 
in doses of 300 mg and is associated with smaller 
decreases in glomerular filtration rate and bone min-
eral density.(25) Whether TAF and ETV have a simi-
lar renal and bone safety profile has not been studied. 
Lamivudine, telbivudine, and TDF have been shown 
to be safe for the fetus when used in the first trimester 
of pregnancy.(27) TDF is preferred because of its high 
barrier to resistance.
ResistanCe to nas
NA treatment may select for viral variants that 
confer resistance. Resistance to NAs leads to virologic 
taBle 1. ViRologiC Responses* to FiRst-line HBV tReatments(13,24)
ETV TDF TAF Pegylated IFN
HBeAg-positive patients
At week 48 or 52
Undetectable HBV DNA 67 67-76 64 25
HBeAg seroconversion 21 12-21 10 27
HBsAg loss 2 <1-3 1 3
During extended treatment or follow-up†
Undetectable HBV DNA 94 (5) 97 (5) 73 (2) 13 (4.5)
HBeAg seroconversion 41 (5) 40 (5) 18 (2) 37 (4.5)
HBsAg loss 5 (5) 10 (5) 1 (2) 8 (4.5)
HBeAg-negative patients
At week 48 or 52
Undetectable HBV DNA 90 93 94 63
HBsAg loss <1 0 0 4
During extended treatment or follow-up†
Undetectable HBV DNA NA 99 (5) 90 (2) 18 (4)
HBsAg loss NA 0 (5) <1 (2) 8 (4)
*Responses presented as %.
†Time point in which response was assessed in years while on treatment for ETV, TDF, or TAF and during off-treatment follow-up 
for pegylated IFN.
Abbreviation: NA, not available.
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breakthrough (>1 log10 increase in HBV DNA from 
nadir while on treatment) that may be accompanied 
by biochemical breakthrough, hepatitis flares, and 
hepatic decompensation. Earlier NAs for hepatitis B 
were associated with very high rates of antiviral drug 
resistance that reached up to 70% after 5 years of lami-
vudine treatment. The risk of antiviral drug resistance 
in patients who are NA naive is ≤1% after 5 years of 
continued treatment with ETV and 8 years with TDF, 
but the risk of resistance to ETV is as high as 50% 
in patients with lamivudine-resistant HBV.(28,29) For 
patients with prior NA exposure, TDF or TAF is 
preferred because mutations conferring resistance to 
lamivudine or telbivudine (M204V/I) constitute the 
first step in the two-hit path to ETV resistance.
pReDiCtoRs oF Response
Among patients who are HBeAg-positive, high ALT 
or histologic activity and low HBV DNA pretreatment 
have been consistently shown to be predictive of higher 
rates of HBeAg loss in response to IFN as well as NA 
therapy. HBV genotype is also a strong predictor of 
IFN-related HBeAg and HBsAg loss.(30) The basis 
for the genotype effect on IFN-induced HBeAg and 
HBsAg loss is unclear. Clinical studies showed that 
patients with genotype A infection do not have lower 
baseline HBeAg or HBsAg levels. Understanding the 
biologic differences in HBV genotypes that contribute 
to a more favorable response of genotype A to IFN 
may help in optimizing the design of new antiviral or 
immunomodulatory therapies. Among patients who 
are HBeAg-negative, there are no consistent baseline 
predictors of response to IFN or NAs. Because of the 
low event rate, predictors of HBsAg loss have not been 
identified for NA therapy, whereas genotype A is the 
only predictor of HBsAg loss for IFN therapy.
In patients who received IFN therapy, lack of or 
suboptimal decline in quantitative HBsAg but not 
HBV DNA has a high negative predictive value for 
response defined as HBeAg loss in patients who are 
HBeAg-positive or sustained off-treatment virus sup-
pression in patients who are HBeAg-negative. This 
has led to the development of stop rules such that 
patients who are predicted not to have a successful 
response may discontinue IFN after 12 or 24 weeks, 
sparing them unnecessary adverse effects.(31) However, 
these stop rules are genotype specific and have not 
been validated in prospective studies.
CHoiCe oF antiViRal DRug 
anD DuRation oF tReatment
For patients who are eligible to receive either IFN 
or NA therapy, the choice depends on patient prefer-
ence and predicted likelihood of response. IFN has to 
be administered as injections and is associated with 
many side effects, but it is given for a finite duration 
and has a higher rate of HBeAg and HBsAg loss, 
particularly for patients with genotype A infection. 
Patients who are HBeAg-positive with genotype A 
infection, high ALT (>2 times normal), and low HBV 
DNA (<8 log10 IU/mL) with no cirrhosis and no con-
traindications to the use of IFN are the best candi-
dates for IFN therapy.
NAs are taken orally and have negligible side effects 
but need to be administered for many years and in 
some patients for life. Thus, willingness to commit to 
a long duration of treatment and ability to adhere to 
the treatment are important deciding factors. ETV, 
TDF, and TAF are preferred NAs. ETV or TAF is 
preferred for patients with underlying renal or bone 
disease. TDF or TAF should be used in patients with 
prior NA exposure. TDF should be used in pregnant 
women and women contemplating pregnancy.
De novo combination of NAs has not been shown 
to be superior to NA monotherapy except for patients 
with very high baseline HBV DNA (>8 log10 IU/mL) 
where a more rapid decline in viremia is achieved with 
combination therapy.(32) Similarly, although com-
bination therapy was initially advocated for patients 
with NA resistance, subsequent studies showed that 
TDF monotherapy has similar efficacy compared to 
a combination of TDF plus emtricitabine in patients 
with lamivudine resistance.(33) Several strategies to 
combine pegylated IFN and NA have been tried, 
including de novo combination, add-on, and switch-to 
approaches. Although some studies have shown a 
benefit compared to monotherapy, the results are not 
consistent and may not be generalized because many 
studies only enrolled highly selected patients.(31) A 
study comparing de novo combination pegylated IFN 
plus TDF versus pegylated IFN or TDF monother-
apy showed that combination therapy was associated 
with a higher rate of HBsAg loss, but this benefit was 
mainly observed in patients with genotype A infec-
tion.(34) Further studies are needed to identify the 
subset of patients who are most likely to benefit and 
to optimize study design of combination therapy with 
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pegylated IFN and NA; however, given the plethora 
of new antiviral and immunomodulatory therapies in 
clinical trials, support for these studies might be dif-
ficult to garner.
Pegylated IFN is administered for 1 year (48-52 
weeks) in both HBeAg-positive and HBeAg-negative 
patients. A clinical trial comparing 24 versus 48 
weeks pegylated IFN in patients who were HBeAg-
positive showed that 24-week duration was infe-
rior.(35) Another trial comparing 48 versus 96 weeks 
of pegylated IFN in patients who were HBeAg-
negative suggests that a 96-week duration is superior, 
but the study included a small number of patients.(36) 
As discussed earlier, the stop rule may be applied at 
week 12 or 24 to identify patients for whom contin-
ued treatment is predicted to be futile.
Guidelines recommend that NA treatment should 
be continued indefinitely in patients with cirrhosis prior 
to the start of treatment.(12-15) The APASL guidelines 
indicate NA may be discontinued in selected patients 
with cirrhosis provided close monitoring is feasible. 
All guidelines recommend that NAs should be admin-
istered for 12 additional months (consolidation) after 
HBeAg seroconversion is achieved in patients who 
are HBeAg-positive with no cirrhosis. Given that 
only 40% of patients achieve HBeAg seroconversion 
after 5 years of ETV or TDF,(37,38) most patients will 
require more than 6 years of treatment. All guidelines 
recommend that NAs can be stopped when HBsAg 
is lost for patients who are HBeAg-negative with 
no cirrhosis, but with <1% of patients achieving this 
outcome after 5 years of treatment, nearly all patients 
will require lifelong treatment. All patients must be 
closely monitored after discontinuation of NA such 
that treatment can be resumed if there is evidence of 
clinical relapse (HBV DNA and ALT increasing to 
levels that meet treatment indications).
Recent studies suggest paradoxically that, for patients 
who are HBeAg-negative who had been virally sup-
pressed for >2 to 3 years, withdrawal of an NA may be 
associated with a higher rate of HBsAg loss compared 
to those who continued the NA.(39-41) This has led the 
APASL and EASL guidelines to include a provision 
for such an approach as long as patients agree to close 
monitoring after treatment is discontinued. However, 
outcomes, including risks of hepatic decompensation, 
frequency of monitoring, and criteria for resuming 
treatment, need to be studied in larger cohorts before 
this approach is widely adopted.
The reason for a higher rate of HBsAg loss after 
NA withdrawal is unclear. It has been postulated that 
viral relapse after a long duration of virus suppression 
may mimic acute hepatitis B, provoking a rigorous 
immune response to HBV leading to HBsAg loss. 
Among patients who experienced clinical relapse, one 
study found that those who did not resume treatment 
had a higher rate of HBsAg loss than those who did, 
suggesting that HBsAg loss is more likely to occur 
if immune clearance is allowed to proceed and not 
be curbed too soon. However, overly rigorous or pro-
longed immune lysis of infected hepatocytes can result 
in liver failure. Moreover, this same study showed 
that patients who had no viral relapse and those who 
had viral but not clinical relapse had higher rates of 
HBsAg loss than those who had clinical relapse, indi-
cating that hepatitis flares are not required for HBsAg 
loss.(40)
The ability to identify which patients will remain 
in remission, which ones will experience viral relapse 
only, which ones will experience clinical relapse, and 
which ones will decompensate when NA is stopped 
is an important area for research. It is also important 
to have a standardized definition for viral and clini-
cal relapse so that data from different studies can be 
compared. Several studies suggest that serum HBsAg, 
HBV RNA, and hepatitis B core related antigen lev-
els, which are surrogate markers for cccDNA, before 
stopping treatment may be predictive.(42) Validation of 
these markers is necessary, and if confirmed, standard-
ized assays must be available for clinical use.
long-teRm outComes
Continued follow-up of patients who completed a 
course of IFN treatment showed that rates of HBeAg 
seroconversion increased to 37% after 4 to 5 years and 
HBsAg loss to 8% after 4 years.(43,44) However, these 
incremental responses were mainly seen in patients 
with genotype A infection. Studies have also shown 
that continued NA treatment is associated with 
increasing rates of HBeAg seroconversion to 40% 
after 5 years of ETV or TDF,(37,38) but there is mini-
mal increase in rates of HBsAg loss.
Antiviral treatment has also been shown to 
improve liver histology. Biopsies performed after 1 
year of treatment showed decreased inflammation 
but not fibrosis, and biopsies performed after 3 to 5 
years of continued NA therapy have demonstrated a 
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decrease in both inflammation and fibrosis. A study 
of 348 patients who had liver biopsies at baseline 
and after 240 weeks of TDF found that 87% had 
decreased inflammation and 52% had decreased fibro-
sis. Importantly, 74% of patients who had cirrhosis 
at enrollment no longer had cirrhosis.(38) It would be 
important to know whether patients who have regres-
sion of cirrhosis have a lower risk of HCC compared 
to those without regression. Liver biopsies, particularly 
serial biopsies, are seldom performed in clinical prac-
tice. Studies using biomarker panels or elastography 
are needed to determine what criteria should be used 
to assess antiviral-induced fibrosis regression because 
these noninvasive methods measure not only fibrosis 
but also inflammation and initial improvement after 
treatment may be due to decreased inflammation and 
not fibrosis.
Antiviral therapy has also been shown to improve 
clinical outcomes. A landmark randomized controlled 
trial showed that lamivudine decreased the risk of dis-
ease progression and HCC in patients with advanced 
fibrosis or cirrhosis.(16) Long-term follow-up studies 
and meta-analyses indicate that IFN and NA therapy 
decrease the development of cirrhosis, cirrhosis com-
plications, HCC, and mortality.(2,45,46) However, the 
incidence of HCC is not eliminated, and continued 
surveillance is required. A recent study showed that 
the incidence of HCC appeared to level off after 5 
years of ETV or TDF in patients with cirrhosis,(47) 
suggesting that with a longer duration of suppressed 
HBV replication and decreased hepatic inflammation, 
development of new HCC can be prevented. In this 
study, all new HCC after year 5 occurred in patients 
>50 years old. These data support the recommenda-
tions to initiate treatment as early as possible. Longer 
follow-up is needed to determine whether the inci-
dence of HCC will eventually stop in patients with 
viral suppression on NAs.
Future of HBV Treatment
The availability of a simple, safe, and highly effec-
tive cure for hepatitis C has reenergized the search for 
a cure for hepatitis B. However, as described earlier, 
a sterilizing cure with elimination of both cccDNA 
and integrated HBV DNA may not be possible. 
Instead, experts agree that a functional cure akin to 
spontaneous HBsAg loss in patients with chronic 
HBV infection may be a realistic goal.(3) The end-
point would be HBsAg loss accompanied by HBeAg 
loss and undetectable HBV DNA in serum, but HBV 
DNA may persist in the liver as integrated HBV DNA 
and as transcriptionally inactive cccDNA. Progression 
of liver disease would be halted, and over time fibro-
sis would regress and the incidence of HCC would 
decrease. Whether seroconversion to hepatitis B sur-
face antibody is necessary to prevent HBsAg serorev-
ersion remains to be determined. This functional cure 
is currently achievable in a small percentage (<10%) of 
patients after IFN or NA therapy. The vision for the 
future is to deploy a combination of antiviral drugs 
directed against new targets and immunomodulatory 
therapies to restore innate as well as adaptive immune 
responses with the goal of achieving HBsAg loss in 
a higher percentage (>50%) of patients after a finite 
course (≥2 years) of treatment. These new strategies 
may or may not include IFN or NAs.
New antiviral drugs in clinical trials include entry 
receptor inhibitors, capsid assembly modifiers, RNA 
interference, and nucleic acid polymers.(3) To date, 
capsid assembly modifiers have shown promising 
results, but the effect on HBsAg levels has been mod-
est and there is a concern for antiviral drug resistance. 
RNA interference has been shown to result in >1 log 
decrease in HBsAg levels, but it has to be adminis-
tered as injections and there is a concern for off-target 
effects. Studies of nucleic acid polymers have shown 
a high rate of HBsAg loss, but the design of those 
studies is complex, the exact mechanism of action of 
nucleic acid polymers is unclear, and marked ALT 
flares were observed in a high percentage of patients; 
thus, safety needs to be established and efficacy needs 
to be confirmed. To date, studies of immune mod-
ulatory therapies, including therapeutic vaccines to 
stimulate T-cell response and toll-like receptor ago-
nists to enhance innate immune response, have had 
limited success. Given the recent success of immune 
therapies in oncology, enthusiasm for immune mod-
ulatory therapies, including check-point inhibitors 
and engineered T cells, remains high. A major con-
cern of immune modulatory therapies is uncontrolled 
immune activation leading to fatal hepatitis flares or 
extrahepatic organ damage.
Major challenges with developing new drugs for 
hepatitis B include safety (given the excellent safety 
profile of NAs), ease of administration (NAs are taken 
as pills once a day), and cost (ETV and TDF are both 
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off patent). However, given the high global burden of 
hepatitis B, the desire to achieve a “cure” with a finite 
course of therapy, and the need to effectively control 
HBV replication at an early stage of chronic HBV 
infection, it is hoped that there will be sufficient inter-
est and commitment from the pharmaceutical indus-
try and the scientific community to work together to 
make an HBV cure a reality in the not too distant 
future.
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